Sector Pulse — August 28, 2026

Technology

Theme

AI infrastructure remains the market’s dominant technology trade, but leadership is narrowing toward companies converting demand into backlog, recurring revenue, margin expansion, or cash flow. High-multiple names without near-term monetization are being punished, while semiconductors, networking, storage, cybersecurity, and enterprise software with measurable AI adoption continue to attract capital.

Movers

  • NVDA(NVIDIA): Q2 revenue rose 106% to $96.2 billion, with data-center sales up 117%. Its $279 billion of supply commitments and expanding role in financing and orchestrating AI infrastructure reinforce its status as the sector’s central platform, but also create concentration and customer-credit risk.
  • AMD(Advanced Micro Devices): A $5 billion Anthropic commitment, the Helios rack platform, and major compute agreements validate AMD as a credible alternative to NVIDIA. The stock’s 63x forward P/E leaves execution risk elevated.
  • AVGO(Broadcom): AI semiconductor revenue rose 143% to $10.8 billion, supported by custom accelerators and a 69% adjusted EBITDA margin. Broadcom is moving beyond chips into AI infrastructure financing, increasing both its strategic relevance and systemic exposure.
  • MRVL(Marvell Technology): Record data-center sales and a $120 billion Google custom-silicon agreement confirm strong positioning, but the deal’s revenue contribution is delayed until 2029. The stock’s repeated post-earnings selloffs show that investors are demanding near-term monetization.
  • MU(Micron Technology), WDC(Western Digital), SNDK(Sandisk), and STX(Seagate Technology): AI-driven HBM, NAND, and nearline-storage demand is driving an unusually powerful memory cycle. The opportunity is structural, but new capacity coming online in 2027–28 raises eventual overcapacity risk.
  • CRM(Salesforce), NOW(ServiceNow), WDAY(Workday), OKTA(Okta), ESTC(Elastic), and PLTR(Palantir): Enterprise AI is shifting from narrative to revenue. Agentforce, AI identity, AI agents, and government-backed platforms are generating measurable bookings and ARR, separating these companies from weaker AI-branded software.
  • SMCI(Super Micro Computer), CRWV(CoreWeave), APLD(Applied Digital), CORZ(Core Scientific), IREN(IREN), and NBIS(Nebius): Demand for GPU capacity remains extraordinary, but the market is differentiating sharply between pre-funded infrastructure and leveraged, cash-burning expansion. IREN’s large hardware impairment triggered a sector-wide repricing.
  • ASML(ASML), KLAC(KLA), LRCX(Lam Research), CDNS(Cadence Design Systems), and SNPS(Synopsys): Semiconductor equipment and design software remain essential bottlenecks in the AI buildout. Their moats are strong, but China export controls and premium valuations remain key risks.
  • AAPL(Apple): Services price increases demonstrate ecosystem pricing power, while leadership and AI restructuring ahead of the September 9 event create a high-stakes credibility test. The market is demanding a compelling AI and hardware roadmap at an elevated valuation.
  • MSFT(Microsoft): Abandoning the Monarch compute campus suggests a more selective approach to AI infrastructure, even as Azure remains dominant. The decision highlights rising capital intensity and the advantage of more agile providers.
  • GOOGL(Alphabet): Cloud growth, AI Overviews, and the $120 billion Marvell custom-silicon deal strengthen Alphabet’s vertically integrated AI strategy. However, OpenAI/Anthropic revenue concentration, rising chip costs, and delayed deal monetization temper the upside.
  • CSCO(Cisco), ANET(Arista Networks), CIEN(Ciena), COHR(Coherent), LITE(Lumentum), CRDO(Credo Technology), MXL(MaxLinear), and NOK(Nokia): Networking and optical infrastructure are benefiting directly from hyperscaler capex. Ciena’s backlog and Credo’s growth are strong, but extreme valuations and customer concentration make the group highly sensitive to any capex pause.
  • NTNX(Nutanix), NTAP(NetApp), PSTG(Everpure), DDOG(Datadog), MDB(MongoDB), SNOW(Snowflake), VEEV(Veeva Systems), and ADSK(Autodesk): Hybrid cloud, observability, data platforms, and vertical software are gaining credibility as AI adoption expands. Nutanix and Elastic stand out for combining growth with cash generation; MongoDB and Snowflake face demanding valuation tests.
  • INTC(Intel): NVIDIA’s reported $30 billion investment is a major validation of Intel’s foundry ambitions, but quarterly foundry losses and a 63x forward P/E leave the turnaround highly binary.
  • PATH(UiPath), PEGA(Pegasystems), TEAM(Atlassian), TYL(Tyler Technologies), GDDY(GoDaddy), GWRE(Guidewire), and DOCU(DocuSign): AI-enabled workflow and vertical software are receiving renewed attention. The key distinction is commercial proof: UiPath’s 8,800-process Banco Azteca deployment is more actionable than broad sector-driven rallies in names such as PTC or Dynatrace.

Actionable Ideas (Positive)

  • AMD(Advanced Micro Devices): The Anthropic commitment and Helios roadmap provide the clearest evidence yet that AMD can become a strategic second source in AI compute. Use pullbacks to build exposure, but size against the 63x forward P/E.
  • ANET(Arista Networks): AI fabrics, 1.6-terabit switching, and strong earnings revisions support a high-conviction infrastructure position. The actionable angle is exposure to networking as the next bottleneck after compute.
  • MU(Micron Technology): HBM scarcity and long-term AI contracts support pricing power and earnings leverage. The trade is bullish while demand exceeds supply, with capacity additions the principal exit signal.
  • OKTA(Okta): AI identity represents 30% of new bookings and lifts average contract values by 40%. This is one of the cleaner ways to express the AI-agent security theme because monetization is already visible.
  • NTNX(Nutanix): Margin expansion, 36.7% free-cash-flow margins, and AI partnerships support a re-rating from infrastructure vendor to profitable hybrid-cloud platform.
  • WDAY(Workday): AI agents are generating more than 25% of new ACV, while margins and retention remain strong. The stock’s position below its 52-week high offers a more attractive entry than many AI software peers.
  • WDC(Western Digital) and STX(Seagate Technology): Persistent data storage is becoming a core AI infrastructure requirement. Both offer leverage to the storage cycle, but positions should be reduced if hyperscaler contracts or pricing weaken.

Actionable Ideas (Negative)

  • CRWV(CoreWeave): $35.1 billion of debt, $640 million of quarterly interest, and a large free-cash-flow deficit make the stock vulnerable if GPU utilization or financing conditions weaken. Avoid chasing the rally; credit risk is the key short thesis.
  • APLD(Applied Digital), CORZ(Core Scientific), and NBIS(Nebius): These high-multiple AI infrastructure names remain vulnerable to contagion from hardware impairments and tighter capital markets. The sector is repricing toward funding quality over headline backlog.
  • MRVL(Marvell Technology): The Google deal is strategically important but offers little near-term revenue support, while the stock trades at a very high multiple. Any timeline slippage should trigger further de-rating.
  • PANW(Palo Alto Networks), CRWD(CrowdStrike), and NOW(ServiceNow): These are excellent businesses, but valuations demand uninterrupted growth and margin expansion. They are better risk-management shorts or put-spread candidates around earnings than fresh long entries.
  • INTC(Intel): The NVIDIA investment improves the long-term narrative but does not solve foundry losses. The upcoming earnings report is a binary test of whether strategic validation is translating into operating improvement.

Financials

Theme

Financials are splitting into two camps: technology-enabled compounders and capital-markets leaders are attracting capital, while banks and asset managers with weak growth, regulatory exposure, or deteriorating credit metrics are lagging. The hawkish Federal Reserve is supportive of some net-interest-income businesses but raises funding, credit, and duration risks across the sector.

Movers

  • JPM(JPMorgan Chase): JPMorgan is consolidating technology M&A talent, expanding private financial infrastructure through JPM Coin and Kinexys, and increasing its influence in public-sector digital transformation. Its strategic advantage is increasingly based on scale plus technology, not simply balance sheet size.
  • GS(Goldman Sachs), MS(Morgan Stanley), and EVR(Evercore): Investment banking and wealth management momentum remains strong. Morgan Stanley’s 27% return on tangible equity and buyback authorization stand out, while Evercore’s earnings miss despite revenue and AUM growth exposes compensation and margin risk.
  • SCHW(Charles Schwab), IBKR(Interactive Brokers), HOOD(Robinhood), SOFI(SoFi), CHYM(Chime Financial), and CPAY(Corpay): Digital finance is expanding through crypto access, AI tools, cross-border payments, and platform cross-selling. The market is rewarding growth, but several names are priced for continued exceptional execution.
  • COIN(Coinbase), PYPL(PayPal), XYZ(Block), AFRM(Affirm), KLAR(Klarna), FISV(Fiserv), and JKHY(Jack Henry): The payments landscape is polarizing. Affirm and Jack Henry delivered tangible operating momentum; PayPal’s failed takeover bid exposed standalone execution concerns; Fiserv’s guidance miss was a clear outlier.
  • BAC(Bank of America), TFC(Truist Financial), and FITB(Fifth Third Bancorp): Regulatory and governance risk intensified after Delaware Life product suspensions and related investigations. Bank of America also faces talent losses in technology M&A and potential GSIB capital constraints.
  • USB(U.S. Bancorp) versus NTRS(Northern Trust): The relative-value gap favors USB, with lower P/E and P/B ratios, better growth-adjusted valuation, and stronger earnings revisions.
  • ALL(Allstate), TRV(Travelers), HIG(The Hartford), WRB(W. R. Berkley), CB(Chubb), PGR(Progressive), CINF(Cincinnati Financial), BRO(Brown & Brown), AON(Aon), and ERIE(Erie Indemnity): Underwriting discipline and investment income remain the core differentiators. Travelers and Brown & Brown show the strongest operating momentum; Aon’s sharp free-cash-flow decline is the clearest negative.
  • AGNC(AGNC Investment), LPLA(LPL Financial), OWL(Blue Owl Capital), TPG(TPG), IVZ(Invesco), and FDS(FactSet): Alternative assets and data services are benefiting from capital rotation, but leverage and valuation dispersion are high. Blue Owl’s IREN financing makes it a direct beneficiary of AI infrastructure growth—and a direct holder of its credit risk.
  • TD(Toronto-Dominion Bank), CM(CIBC), BNS(Bank of Nova Scotia), BBVA(BBVA Banco Frances), BCS(Barclays), DB(Deutsche Bank), HSBC(HSBC), UBS(UBS), MFC(Manulife Financial), and SLF(Sun Life): Canadian and global banks are showing stronger capital-markets and wealth performance, but credit costs, compliance expenses, and capital requirements remain important offsets.

Actionable Ideas (Positive)

  • TRV(Travelers): Four earnings beats, a sub-90% underlying combined ratio, and positive estimate revisions support a high-conviction long. Travelers offers defensive financial exposure with operating momentum.
  • USB(U.S. Bancorp): USB combines a lower valuation with stronger growth-adjusted metrics than Northern Trust. The actionable angle is a long USB/short NTRS relative-value trade.
  • AFRM(Affirm): Revenue, GMV, active users, and operating margins are all accelerating, while delinquencies are improving. The FY2027 margin outlook above 30.5% supports continued upside, although volatility will remain high.
  • IBKR(Interactive Brokers): A 77% pretax margin, 36% DART growth, and automated global infrastructure provide unusually strong operating leverage. The stock is a preferred long among digitally scalable brokers.
  • SCHW(Charles Schwab): Adding SOL, AVAX, and LINK to a 39-million-client platform can improve retention and wallet share. The opportunity is ecosystem monetization, not near-term crypto trading revenue.

Actionable Ideas (Negative)

  • AON(Aon): Operating cash flow fell 30% and adjusted free cash flow declined 34% despite reaffirmed growth targets. Short or underweight until cash conversion validates management’s outlook.
  • BAC(Bank of America): GSIB capital pressure, talent attrition, weak net interest margins, and compliance damage create a poor risk-reward profile relative to JPMorgan.
  • FISV(Fiserv): The revenue decline and full-year EPS guidance miss indicate a material execution problem in a sector where peers are gaining share. Avoid until the company demonstrates stabilization.
  • NTRS(Northern Trust): Weak growth and unprofitable incremental sales do not justify its premium valuation to USB.
  • IVZ(Invesco): Stagnant sales, falling EPS, and 5x net debt/EBITDA make the low P/E a value trap rather than a catalyst.

Healthcare

Theme

Healthcare news is being driven by clinical differentiation, diagnostic platforms, and payer pressure. Innovative metabolic, oncology, genetic, and chronic-care products are gaining strategic value, while insurers and providers face margin pressure from medical costs, exchange-market disruption, and regulatory intervention.

Movers

  • LLY(Eli Lilly), NVO(Novo Nordisk), and ABBV(AbbVie): Metabolic and immunology remain the industry’s strongest growth engines. Mounjaro’s cardiovascular-risk reduction approval broadens Lilly’s addressable market, while Novo’s delayed Chinese oral-Wegovy launch creates an execution gap. AbbVie’s subcutaneous Skyrizi formulation is designed to defend share against oral competitors.
  • ABT(Abbott Laboratories), DXCM(DexCom), and PODD(Insulet): Abbott’s FDA clearance of Libre Duo, the first continuous glucose-and-ketone monitor, materially changes the competitive landscape. Its planned pump integrations create ecosystem risk for DexCom.
  • MRNA(Moderna), MRK(Merck), and RHHBY(Roche): Moderna’s successful Phase 3 personalized cancer vaccine trial validates mRNA oncology but triggered a 177% stock surge despite ongoing losses and new convertible debt. Merck gains a potential Keytruda life-cycle extension, while Roche faces a setback from the halted BioNTech mRNA trial but positive Vabysmo and diagnostic developments.
  • GILD(Gilead), JNJ(Johnson & Johnson), PFE(Pfizer), and TAK(Takeda): New HIV, immunology, rare-disease, vaccine, and hematology approvals reinforce pipeline quality. J&J’s Stelara erosion and talc liabilities remain offsets; Takeda’s MIMRYLO approval is a meaningful rare-disease catalyst.
  • ALNY(Alnylam), IONS(Ionis Pharmaceuticals), and BBIO(BridgeBio Pharma): Wainua’s Phase 3 failure is damaging the RNA-silencing thesis in ATTR-CM while strengthening the case for oral stabilizers such as BridgeBio’s Vyndamax.
  • CVS(CVS Health), ELV(Elevance Health), HUM(Humana), MOH(Molina Healthcare), UNH(UnitedHealth), and HCA(HCA Healthcare): Payer and provider stocks are under pressure from cost inflation, exchange disenrollment, Medicare Advantage volatility, and antitrust scrutiny. CVS’s ACA exit across 17 states is the clearest sign of structural stress.
  • ISRG(Intuitive Surgical), GMED(Globus Medical), TFX(Teleflex), BSX(Boston Scientific), GEHC(GE HealthCare), EW(Edwards Lifesciences), and SYK(Stryker): Medical devices continue to deliver durable demand, but valuations are increasingly important. Boston Scientific’s WATCHMAN slowdown and reduced guidance contrast with strong growth at Globus and Teleflex.
  • LH(Labcorp), NTRA(Natera), TXG(10x Genomics), ROP(Roche Holding), VCYT(Veracyte), and ILMN(Illumina): Precision diagnostics are gaining strategic importance through blood-based Alzheimer’s testing, ctDNA monitoring, genomics IP, and multiomics. Labcorp’s pTau217 test and Natera’s Signatera adoption are especially meaningful platform catalysts.
  • IQV(IQVIA), MEDP(Medpace), DVA(DaVita), UTHR(United Therapeutics), CRSP(CRISPR Therapeutics), NBIX(Neurocrine), and TFX(Teleflex): Clinical outsourcing and specialty therapeutics are showing tangible growth, while AI is becoming an enabling layer rather than a standalone narrative.
  • HIMS(Hims & Hers), COO(CooperCompanies), ELAN(Elanco), INCY(Incyte), SMMT(Summit Therapeutics), and VKTX(Viking Therapeutics): These names face varying combinations of cash burn, margin deterioration, regulatory risk, or absent commercialization.

Actionable Ideas (Positive)

  • LLY(Eli Lilly): The Mounjaro cardiovascular indication materially expands prescription potential and payer relevance. Maintain a structural long bias on metabolic care, with product concentration as the principal risk.
  • ABT(Abbott Laboratories): Libre Duo creates a differentiated metabolic-monitoring ecosystem and threatens DexCom’s positioning. Abbott is the preferred long in diabetes technology.
  • NTRA(Natera): Signatera’s integration into oncology trials and European IVDR certification support recurring, high-value diagnostic revenue. Buy on weakness tied to the limited immediate reaction.
  • DVA(DaVita): The Humana partnership shifts DaVita toward coordinated, value-based chronic care. Successful scaling could support a multiple expansion from dialysis provider to care-platform operator.
  • CRSP(CRISPR Therapeutics): CTX310’s durable lipid reductions after a single infusion create a genuine platform-level catalyst. The next clinical readout is the key validation point.

Actionable Ideas (Negative)

  • ALNY(Alnylam) and IONS(Ionis Pharmaceuticals): Wainua’s failed ATTR-CM trial weakens confidence in silencer combination therapy and raises the burden of proof for injectable alternatives. The sector’s preference is shifting toward oral stabilizers.
  • DXCM(DexCom): Abbott’s Libre Duo directly challenges DexCom in pediatric and pump-integrated markets. Underweight until DexCom demonstrates a competitive response.
  • MOH(Molina Healthcare): Member losses, falling EPS, and sharply reduced estimates point to a fundamental deterioration in government-sponsored insurance economics.
  • HIMS(Hims & Hers): FTC litigation, billing complaints, shrinking margins, and cash burn create a credible threat to the subscription model. The stock remains a high-conviction short on regulatory weakness.

Industrials

Theme

Industrials are benefiting from defense spending, grid modernization, aerospace aftermarket demand, and AI-related construction, but valuation discipline is returning. Companies with contractual visibility and cash generation are outperforming capital-intensive stories that rely on future execution.

Movers

  • GE(GE Aerospace), HWM(Howmet Aerospace), RTX(RTX), GD(General Dynamics), LHX(L3Harris), KTOS(Kratos), AVAV(AeroVironment), CW(Curtiss-Wright), and TDG(TransDigm): Defense and aerospace remain the strongest industrial subtheme. RTX’s $22.9 billion Tomahawk contract, GD’s $136.5 billion backlog, and LHX’s Viper Shield expansion provide tangible visibility. AVAV and KTOS offer higher-beta exposure with weaker current cash generation.
  • CAT(Caterpillar), DE(Deere), URI(United Rentals), EME(EMCOR), PWR(Quanta Services), MTZ(MasTec), FIX(Comfort Systems), ETN(Eaton), and HUBB(Hubbell): AI data centers and grid investment are driving construction and power-management demand. EME’s $17.1 billion RPO and MTZ’s $21.4 billion backlog are especially strong, while PWR and FIX trade at demanding multiples.
  • APH(Amphenol), GLW(Corning), DOV(Dover), GWW(W.W. Grainger), GGG(Graco), NDSN(Nordson), ROK(Rockwell Automation), MTD(Mettler-Toledo), WAB(Westinghouse Air Brake), WWD(Woodward), and 3M(MMM): Industrial technology and distribution remain resilient, though some stocks are priced for uninterrupted growth. Amphenol’s 55% revenue growth and 29.8% operating margin are sector-leading.
  • BA(Boeing): Defense revenue and backlog are improving, but an 88% debt-to-capital ratio and SPEEA strike authorization create a severe operational and balance-sheet risk.
  • HON(Honeywell), APTV(Aptiv), CSL(Carlisle), MAS(Masco), VMC(Vulcan Materials), SPXC(SPX Technologies), and PCAR(PACCAR): These names face varying combinations of weak demand, estimate cuts, cost inflation, or cyclical exposure.

Actionable Ideas (Positive)

  • EME(EMCOR): A $17.1 billion, 95%-organic RPO base gives strong revenue visibility into AI data-center and infrastructure construction. Prefer EME as a core infrastructure long.
  • APH(Amphenol): Record orders, 1.23 book-to-bill, 30% organic growth, and expanding margins confirm structural demand across AI, aerospace, and harsh environments.
  • GD(General Dynamics): GD offers the best combination of defense backlog, balance-sheet strength, and earnings visibility. It is a preferred defensive-growth holding versus Boeing.
  • HWM(Howmet Aerospace): Commercial aerospace growth, defense demand, and the CAM acquisition support a durable aftermarket and components thesis. The stock is expensive, but earnings revisions remain supportive.
  • DE(Deere): Deere’s construction backlog and precision-agriculture strategy are being overlooked because of indiscriminate data-center sentiment. Long DE/short CAT is attractive on relative valuation and execution.

Actionable Ideas (Negative)

  • BA(Boeing): Strike risk at critical certification programs, extreme leverage, and weak interest coverage make Boeing the sector’s clearest avoid.
  • HON(Honeywell): Forecast EPS and revenue collapses are incompatible with a 26.7x forward P/E. The stock remains exposed to a valuation reset.
  • APTV(Aptiv): A 10.1% earnings-estimate cut and automotive-sector weakness indicate a structural earnings reset rather than a routine cyclical dip.
  • PWR(Quanta Services) and FIX(Comfort Systems): Strong backlogs are already reflected in valuations of 70.5x and 35.2x forward earnings, respectively. Underweight where execution fails to accelerate.
  • VMC(Vulcan Materials): Diesel inflation is compressing EBITDA margins despite pricing power. Continued downstream divestitures also reduce future growth optionality.

Transportation

Theme

Transportation is being shaped by premium travel, rail efficiency, cross-border logistics, and constrained freight capacity. The best operators are converting volume into pricing and margin, while weaker companies remain exposed to fuel, labor, merger, and utilization risks.

Movers

  • DAL(Delta Air Lines) versus AAL(American Airlines): Delta’s premium strategy generates nearly 60% of adjusted revenue from diversified sources, while American’s delayed seatback-screen rollout underscores a widening competitive gap. American’s low profit relative to Delta highlights a structural, not cosmetic, disadvantage.
  • FDX(FedEx), UPS(United Parcel Service), UNP(Union Pacific), NSC(Norfolk Southern), CP(Canadian Pacific Kansas City), CSX(CSX), and CNI(Canadian National Railway): Efficiency and network quality are separating winners from laggards. Union Pacific’s 59.2% operating ratio contrasts sharply with Norfolk Southern’s 65.5%; FedEx is executing a turnaround while absorbing institutional selling.
  • ZIM(ZIM Integrated Shipping Services), XPO(XPO), ODFL(Old Dominion Freight Line), FTAI(FTAI Aviation), CNI(Canadian National Railway), and TFII(TFI International): Cross-border and specialized logistics remain attractive, but merger uncertainty and high valuations create asymmetric risks.
  • CCL(Carnival), NCLH(Norwegian Cruise Line), H(Hyatt Hotels), and IHG(Inter

This content is for informational purposes only and does not constitute financial, investment, or trading advice. Always consult a qualified financial professional before making any investment decisions.